Results 21 to 30 of about 43,463 (255)
A new visual rating scale for Ioflupane imaging in Lewy body disease
NeuroImage: Clinical, 2018 Background: Dopaminergic loss on 123I-Ioflupane brain imaging is a recognised biomarker for dementia with Lewy bodies. It is usually assessed using a visual rating scale developed for Parkinson's disease, which may not be optimal for dementia with Lewy ...
Jim J. Lloyd +7 more
doaj +1 more source
Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease
Molecular Neurodegeneration, 2009 Lewy bodies and Lewy neurites constitute the cardinal neuropathological features of both Parkinson's disease (PD) and Lewy body dementia (LBD). Whereas α-synuclein has been found to be the major component of the Lewy body, the mechanisms by which neurons
Perry George +12 more
doaj +1 more source
Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева, 2018 Te lecture presents modern concept of the symptoms, diagnosis and treatment of dementia with Lewy bodies (DLB), which accounts for about 10% of cases of dementia. Te nosological status of DLB and the problem of ratio of DLB and Parkinson’s disease which,
O. S. Levin +3 more
doaj +1 more source
Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium
Frontiers in Neurology, 2022 The Lewy Body Dementia Association (LBDA) held a virtual event, the LBDA Biofluid/Tissue Biomarker Symposium, on January 25, 2021, to present advances in biomarkers for Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLBs) and ...
Gregory D. Scott +54 more
doaj +1 more source
International Journal of Islamic Education, Research and MulticulturalismDementia Lewy Body (DLB) is a form of dementia characterized by abnormal accumulation of α-synuclein protein in the brain, forming lewy bodies that damage the function of neurons and nervous system.
Lubna Afina +4 more
doaj +1 more source
Advances in dementia with Lewy bodies
Therapeutic Advances in Neurological Disorders, 2021 Dementia with Lewy bodies (DLB) is a clinical diagnosis representing a specific presentation of a pathological α-synucleinopathy (Lewy body disease). DLB is one entity under the broader term Lewy body dementia , which also includes Parkinson’s disease ...
Melissa J. Armstrong
doaj +1 more source
Lewy body disease and dementia with Lewy bodies
Proceedings of the Japan Academy, Series B, 2014 In 1976 we reported our first autopsied case with diffuse Lewy body disease (DLBD), the term of which we proposed in 1984. We also proposed the term "Lewy body disease" (LBD) in 1980. Subsequently, we classified LBD into three types according to the distribution pattern of Lewy bodies: a brain stem type, a transitional type and a diffuse type.
openaire +3 more sources
More than a rumor spreads in Parkinson’s disease.
Frontiers in Human Neuroscience, 2016 As Parkinson's disease progresses, a massive loss of dopaminergic neurons is accompanied by accumulation of alpha-Synuclein (αSyn) neuronal inclusions called Lewy bodies and Lewy neurites.
Natalia Cecilia Prymaczok +2 more
doaj +1 more source
Common age‐related neuropathologies and yearly variability in cognition
Annals of Clinical and Translational Neurology, 2019 Objective Cognitive variability is a potentially important source of heterogeneity in longitudinal cognitive profiles. We examined the extent to which common age‐related neuropathologies including Lewy bodies and Alzheimer’s disease (AD) contribute to ...
Lei Yu +6 more
doaj +1 more source
Effects of α-synuclein on axonal transport
Neurobiology of Disease, 2017 Lewy bodies and Lewy neurites composed primarily of α-synuclein characterize synucleinopathies including Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB).
Laura A. Volpicelli-Daley
doaj +1 more source